首页 | 本学科首页   官方微博 | 高级检索  
     

表皮生长因子受体信号通路在维吾尔族妇女宫颈癌中的表达研究
引用本文:王晓倩 史永华 常珩 塔拉甫·托坎 美力班·吐尔逊. 表皮生长因子受体信号通路在维吾尔族妇女宫颈癌中的表达研究[J]. 现代生物医学进展, 2014, 14(20): 3835-3839
作者姓名:王晓倩 史永华 常珩 塔拉甫·托坎 美力班·吐尔逊
作者单位:1 新疆医科大学研究生学院新疆乌鲁木齐830054;2 新疆医科大学基础医学院病理教研室新疆乌鲁木齐830011;3 兰州军区乌鲁木齐总医院新疆乌鲁木齐830000
基金项目:新疆维吾尔自治区自然科学基金面上项目(2012211A041)
摘    要:目的:随着表皮生长因子受体(epidermal growth factor receptor,EGFR)靶点治疗药物在其它肿瘤治疗中的应用,能否在妇科肿瘤中应用并取得疗效,已经得到学者们的重视。但在临床应用之前,必须明确EGFR与妇科肿瘤发生发展的关系及其机制。因此,我们来探讨表皮生长因子受体EGFR信号通路在维吾尔族不同级别宫颈病变组织中的差异表达及其临床意义。方法:应用免疫组织化学方法检测EGFR、P-EGFR、ERK 1/2、P-ERK1/2在108例子宫颈癌,47例CIN,79例正常宫颈组织中的表达,并分析其与临床病理参数的关系。结果:EGFR在子宫颈癌、CIN及正常宫颈组织中的阳性表达率分别是74.10%、66%、27.80%(P0.01);P-EGFR在三组间的阳性表达率分别是55.60%、74.50%、20.30%(P0.01);ERK1/2在三组间的阳性表达率分别是60.10%、76.60%、25.30%(P0.01);P-ERK1/2在三组间的阳性表达率分别是44.40%、66%、24.10%(P0.01),其在宫颈癌中EGFR与与浸润深度、淋巴结转移有关;ERK与肿瘤的临床分期、远处转移有关,而且在宫颈癌中EGFR与P-EGFR、ERK 1/2、P-ERK1/2的表达成正相关(P0.05)。结论:EGFR、P-EGFR、ERK1/2、P-ERK1/2的表达与宫颈癌的发生、发展相关,促进宫颈癌的浸润和转移,抑制EGFR信号通路可能为多靶点联合治疗宫颈癌提供新的方向。

关 键 词:EGFR;ERK1/2;宫颈癌

Research on Expression of Epidermal Growth Factor ReceptorSignaling Pathway in Cervical Carcinoma in Uighur Women*
WANG Xiao-qian,SHI Yong-hu,CHANG Heng,Talafu tuokan,Meiliban tuerxum. Research on Expression of Epidermal Growth Factor ReceptorSignaling Pathway in Cervical Carcinoma in Uighur Women*[J]. Progress in Modern Biomedicine, 2014, 14(20): 3835-3839
Authors:WANG Xiao-qian  SHI Yong-hu  CHANG Heng  Talafu tuokan  Meiliban tuerxum
Abstract:ABSTRACT Objective:With the application of epidermal growth factor receptor (EGFR) target therapy in various types ofoncotherapy, it has obtained much attention from scholars that whether it can be applied to gynecological tumors with certain curativeeffects. But it is necessary to find out its relation with the occurrence of gynecologic cancer as well as the development of its mechanism.Therefore, in this study we are to investigate different expressions and clinical significance of epidermal growth factor receptor (EGFR)signal pathway in cervical lesions tissues of different grades in Uygur women. Methods:Immunohistochemistry is used to detect EGFR,P-EGFR, ERK1/2,P-ERK1/2 in 108 cases of cervical cancer, 47 cases of CIN and 79 cases of normal cervical tissues and analyzes theirrelationship with clinicopathological parameters.Results: EGFR expression rates in cervical cancer, CIN and normal cervical tissues were74.10%, 66% and 27.80%(P<0.01), respectively; P-EGFR expression rates among the three groups were 55.60%, 74.50% and 20.30%(P<0.01), respectively; ERK1/2 expression rates among the three groups were 60.10%, 76.60% and 25.30%(P<0.01), respectively;P-ERK1/2 expression rates among the three groups were 44.40%, 66% and 24.10%(P<0.01), respectively. Their expressions in cervicalcarcinoma were correlated with tumor invasion, lymphatic metastasis; ERK1/2 expressions were correlated with clinical stage, distantmetastasis; and EGFR and P-EGFR, ERK1/2, P-ERK1/2 in expression was positively correlated (P<0.05).Conclusion: Expressions ofEGFR, P-EGFR, ERK1/2 and P-ERK1/2 are correlated with occurrence and development in cervical cancer. Promoting cancer invasionand metastasis, and inhibiting EGFR signaling pathway may provide a new direction to multi-target combination therapy of cervicalcancer.
Keywords:EGFR   ERK1/2   Cervical carcinoma
本文献已被 CNKI 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号